Adenosine A2A receptor deficient mice are partially resistant to limbic seizures

被引:55
作者
El Yacoubi, Malika [1 ]
Ledent, Catherine [2 ]
Parmentier, Marc [2 ]
Costentin, Jean [1 ]
Vaugeois, Jean-Marie [1 ]
机构
[1] UFR Med & Pharm, CNRS, Unite Neuropsychopharmacol Expt, FRE 2735,IFRMP 23, F-76183 Rouen, France
[2] Univ Libre Bruxelles, IRIBHM, B-1070 Brussels, Belgium
关键词
A(2A) receptor knockout mice; Pentylenetetrazol; Pilocarpine; Kindling; Convulsants; TEMPORAL-LOBE EPILEPSY; PENTYLENETETRAZOL-INDUCED SEIZURES; LONG-TERM TREATMENT; ENDOGENOUS ADENOSINE; STATUS-EPILEPTICUS; GLUTAMATE RELEASE; RAT HIPPOCAMPUS; NERVE-TERMINALS; BRAIN-DAMAGE; MOUSE-BRAIN;
D O I
10.1007/s00210-009-0426-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The neuromodulator adenosine, acting through activation of four defined metabotropic receptors called A(1), A(2A), A(2B) and A(3,) has been proposed as an endogenous anticonvulsant. Here, the consequences of deleting the adenosine A(2A) receptor have been examined in different experimental models of epilepsy. A(2A)R KO mice were not protected against seizures originating from brainstem structures, namely electroshock-induced seizures. The intensities of seizures induced by pentylenetetrazol or pilocarpine, as well as the percentages of convulsing mice, were significantly reduced in A(2A) receptor knockout (A(2A)R KO) animals. A(2A)R KO mice exhibited reduced pentylenetetrazol-induced kindled seizures, demonstrating an important role of the A(2A) receptor in the acquisition of kindling. These data suggest that adenosine stimulating A(2A) receptors modulates excitatory neurotransmission and exacerbates limbic seizures. It is therefore suggested that adenosine A(2A) receptor antagonists might offer protection from some epileptic syndromes.
引用
收藏
页码:223 / 232
页数:10
相关论文
共 81 条
[1]   CHANGES IN SEIZURE LATENCY CORRELATE WITH ALTERATIONS IN A1 ADENOSINE RECEPTOR-BINDING DURING DAILY REPEATED PENTYLENTETRAZOL-INDUCED CONVULSIONS IN DIFFERENT MOUSE-BRAIN AREAS [J].
ANGELATOU, F ;
PAGONOPOULOU, O ;
KOSTOPOULOS, G .
NEUROSCIENCE LETTERS, 1991, 132 (02) :203-206
[2]  
AULT B, 1987, BRAIN RES, V546, P69
[3]   Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists [J].
Behan, WMH ;
Stone, TW .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (06) :1435-1442
[4]   Evidence for increased dorsal hippocampal adenosine release and metabolism during pharmacologically induced seizures in rats [J].
Berman, RF ;
Fredholm, BB ;
Aden, U ;
O'Connor, WT .
BRAIN RESEARCH, 2000, 872 (1-2) :44-53
[5]   Adenosine and epilepsy: From therapeutic rationale to new therapeutic strategies [J].
Boison, D .
NEUROSCIENTIST, 2005, 11 (01) :25-36
[6]   Adenosine-based cell therapy approaches for pharmacoresistant epilepsies [J].
Boison, Detlev .
NEURODEGENERATIVE DISEASES, 2007, 4 (01) :28-33
[7]   Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists [J].
Bona, E ;
Aden, U ;
Gilland, E ;
Fredholm, BB ;
Hagberg, H .
NEUROPHARMACOLOGY, 1997, 36 (09) :1327-1338
[8]   Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy [J].
Bonan, CD ;
Walz, R ;
Pereira, GS ;
Worm, PV ;
Battastini, AMO ;
Cavalheiro, EA ;
Izquierdo, I ;
Sarkis, JJF .
EPILEPSY RESEARCH, 2000, 39 (03) :229-238
[9]  
BROWNING RA, 1985, FED PROC, V44, P2425
[10]  
BROWNING RA, 1992, DRUGS CONTROL EPILEP, P195